MabPlex International Ltd, a Contract Development and Manufacturing Organization (CDMO), closed its $59.1m series A funding.
This round was led by China’s State Development & Investment Corporation (SDIC) and Shenzhen Venture capital.
The company intends to use the funds to upgrade its technology platform as well as expand commercial production domestically and abroad.
Led by Jianmin Fang, Ph.D, Chairman and Chief Executive Officer, MabPlex International is a Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China and the United States.
Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering services from biologics drug development to commercial manufacturing.